In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

ImmunoGen, CytomX swap licenses to develop anti-cancer Probody-drug conjugates

Executive Summary

In a multi-year deal, next-generation antibody developer CytomX Therapeutics Inc. and ImmunoGen Inc. (antibody-drug conjugates; ADCs) agreed to develop anti-cancer Probody-drug conjugates (PDCs) against a certain number of targets. (NOTE: the lab code of one candidate is CD166, and another is CX2009).
Deal Industry
  • Biotechnology
    • Drug Discovery Tools
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
      • Site Specific
Deal Status
  • Final
Deal Type
  • Alliance
    • R+D and Marketing-Licensing
    • Intra-Biotech Deal
    • Includes Contract
    • Product or Technology Swap

Related Companies

Advertisement
UsernamePublicRestriction

Register